ZhouLSuttonGMRochfordJJ. Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways. Cell Metab. 2007;6:398-405.
5.
O’NeilPSmithSWeissmanN. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426-1436.
6.
SmithSWeissmanNAndersonC. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245-256.
7.
FidlerMCSanchezMRaetherB. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067-3077.
8.
PL Detail-Document, Drugs for Weight Loss. Pharmacist’s Letter/Prescriber’s Letter. July2013.
9.
GaddeKAllisonDRyanD. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341-1352.
10.
GarveyWRyanDLookM. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95:297-308.
